Dyslipidemias in patients with HIV/aids using antiretroviral therapy

Abstract

Submitted by Franciele Moreira ([email protected]) on 2017-09-21T19:59:43Z No. of bitstreams: 2 Dissertação - Max Weyler Nery - 2007.pdf: 1699711 bytes, checksum: d80084feaadd8efb9292ed3849018d55 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Approved for entry into archive by Luciana Ferreira ([email protected]) on 2017-09-22T11:41:38Z (GMT) No. of bitstreams: 2 Dissertação - Max Weyler Nery - 2007.pdf: 1699711 bytes, checksum: d80084feaadd8efb9292ed3849018d55 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2017-09-22T11:41:38Z (GMT). No. of bitstreams: 2 Dissertação - Max Weyler Nery - 2007.pdf: 1699711 bytes, checksum: d80084feaadd8efb9292ed3849018d55 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2007-03-30Background: in a decade of highly active antiretroviral therapy (HAART), morbidity and mortaliy of aids remarkable decreased, however prolonged treatment has been associated with adverse effects, mainly metabolic abnormalities. Objective: to determine the prevalence and risk factors for dyslipidemia among patients on HAART, in Goiânia-Goiás-Brazil. Methods: a cross-sectional study was conducted in adults on HAART, during 2005 and 2006. Patients were interviewed; their medical and laboratory records abstracted and blood obtained for lipid measurements. Dyslipidemia was defined as CT 240 mg/dL, LDL 160 mg/dL, TG > 200 and/or HDL 350 cel/mL. Half (50.4%) of them were on nucleoside reverse transcriptase inhibitors (NTRIs) plus non-nucleoside reverse transcriptase inhibitors (NNTRIs); 42.5% were on NTRI plus protease inhibitors (PIs). Prevalence of dyslipidemia was 66.7%, being HDL 200 mg/dL (36.1%). Patients on PIs based regimen showed a 5.2 higher risk (CI95% 1.8-14.8) of dyslipidemia after adjusting by gender, age and HIV/aids disease onset. Conclusion: disclosed a high prevalence of dyslipemia and point out for interventions programs to reduce future cardiovascular events.Introdução: em dez anos de terapia antirretroviral potente (HAART) houve uma importante redução da morbi-mortalidade da aids, entretanto, o uso prolongado dessas drogas tem sido associado com efeitos adversos frequentes, sobretudo, alterações metabólicas. Objetivo: determinar a prevalência e avaliar fatores de risco para dislipidemias em pacientes em uso de HAART, em Goiânia-Goiás-Brasil. Método: estudo de prevalência conduzido em adultos utilizando HAART, entre 2005 e 2006. Realizada entrevista, revisão de prontuários e coleta de sangue para avaliação do perfil lipídico. Considerou-se dislipidemias quando CT 240 mg/dL, LDL 160 mg/dL, TG > 200 mg/dL e/ou HDL 350 cel/mL. Metade (50,4%) usava inibidores da transcriptase reversa análogo nucleosídeo (ITRNs) com inibidores da transcriptase reversa análogo não nucleosídeo (ITRNNs) e 42,5% usavam ITRNs com inibidores de protease (IPs). A prevalência de dislipidemia foi de 66,7%, sendo a alteração mais frequente HDL 200 mg/dL (36,1%). Pacientes em uso de esquemas contendo IPs apresentaram risco 5,2 vezes maior (IC95% 1,8-14,8) de dislipidemia, após ajuste por sexo, idade e tempo de HIV/aids. Conclusão: foi evidenciada elevada frequência de dislipidemia, sinalizando para a necessidade de intervenções com a finalidade de reduzir eventos cardiovasculares futuros